- Policy
- Rapidly changing breast cancer treatment
- by Choi, sun May 11, 2023 05:49am
- The Korean Breast Cancer Society revised the treatment recommendation on the 27th. Combination drug treatment using a combination of an antibody and an anticancer drug has emerged as a hot issue, and as the new anticancer drug Enhertu for HER2-positive metastatic breast cancer received domestic approval in September last year, the reflection of
- Company
- Scemblix can be prescribed at general hospitals
- by Eo, Yun-Ho May 11, 2023 05:48am
- Novartis' new chronic myelogenous leukemia drug Scemblix is entering prescription rights in general hospitals. According to related industries, Novartis Korea's Ph+CML Philadelphia chromosome-positive chronic myeloid leukemia treatment drug Scemblix has been approved by the Drug Committee (DC) of medical institutions such as Seoul St. Mary
- Opinion
- [Reporter’s View] MSD Korea ‘Calm before the storm’
- by Jung, Sae-Im May 11, 2023 05:46am
- “There were rumors from a month ago, but they proved true. I am at a loss for words at the announcement that the department will be closed down." With the news that MSD Korea’s blockbuster antidiabetic treatment ‘Januvia Series’ will be handed over to Chong Kun Dang, the employees at MSD Korea received the crushing news that the compa
- Company
- Scemblix can be prescribed at general hospitals
- by Eo, Yun-Ho May 10, 2023 11:18pm
- Novartis' new chronic myelogenous leukemia drug Scemblix is entering prescription rights in general hospitals. According to related industries, Novartis Korea's Ph+CML Philadelphia chromosome-positive chronic myeloid leukemia treatment drug Scemblix has been approved by the Drug Committee (DC) of medical institutions such as Seoul St. Mar
- Company
- Negotiation on the price of Onureg has started
- by Eo, Yun-Ho May 10, 2023 11:17pm
- Suggestion of treatment options for patients unable to undergo hematopoietic stem cell transplantation Onureg, an acute myelogenous leukemia maintenance treatment drug, recently entered into drug price negotiations for insurance coverage. After passing the HIRA Cancer Disease Review Committee in December of last year and the Pharmaceutica
- Policy
- A benefit study of the Gardasil 9 NIP is also forthcoming
- by Lee, Jeong-Hwan May 10, 2023 11:17pm
- The KDCA is ordering an additional policy research service to apply the National Vaccination Support Project (NIP) of the 'HPV 9-valent vaccine' to female adolescents and male adolescents over 12 years of age. As the result of the HPV 9 commissioned by KDCA to NECA earlier was found to be low in cost-effectiveness in vaccine research, it is
- Policy
- Prior HIRA approval is required to administer Crysvita
- by Lee, Tak-Sun May 10, 2023 06:00am
- Prior approval from the Health Insurance Review and Assessment Service will be required to administer the pediatric rickets treatment Crysvita Inj which is set to be reimbursed from May this year. Accordingly, HIRA has prepared the specifics for Crysvita’s prior approval and applied it from the 3rd of this month. According to the spe
- Company
- Forxiga, has the largest number of clinical trials
- by Jung, Sae-Im May 10, 2023 05:58am
- With the expansion of SGLT-2 inhibitor coverage, which began in April, combination prescriptions of various diabetes drugs and SGLT-2 drugs are expected to increase. However, as the clinical basis for each drug is a prerequisite for the expansion of this benefit, there are differences in detailed application depending on the presence or absence
- Company
- Betmiga generics’ market share rises to 49%...
- by Kim, Jin-Gu May 9, 2023 05:38am
- Generic versions of mirabegron have increased their influence in Korea’s overactive bladder market. The overall market share of the generic products in Q1 was 49%, chasing sales of the original drug, ‘Betmiga,’ right under the nose. In particular, sales of Hanmi Pharmaceuticals ‘Mirabek’ and Chong Kun Dang’s ‘Selebeta’ have shown
- Policy
- Insurance price ceiling reeval results to be notified soon
- by Lee, Tak-Sun May 9, 2023 05:38am
- The Health Insurance Review and Assessment Service completed its first review on drugs subject to primary pricing ceiling reevaluations and will be notifying companies of the results soon. A 30-day objection period will follow HIRA’s result notification. According to HIRA on the 8th, HIRA’s Drug Reimbursement Evaluation Committee c
